Response and progression in recurrent malignant glioma
Loading...
Date
Authors
Hess, K. R.
Wong, E. T.
Jaeckle, K. A.
Kyritsis, A. P.
Levin, V. A.
Prados, M. D.
Yung, W. K.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Neuro Oncol
Book name
Book series
Book edition
Alternative title / Subtitle
Description
In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11%) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9%). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48% for response and 28% for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95% confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.
Description
Keywords
Actuarial Analysis, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Astrocytoma/drug therapy/mortality/radiotherapy, Brain Neoplasms/*drug therapy/mortality/radiotherapy, Carboplatin/administration & dosage, Combined Modality Therapy, Disease Progression, Disease-Free Survival, Eflornithine/administration & dosage, Female, Fluorouracil/administration & dosage, Glioblastoma/drug therapy/mortality/radiotherapy, Glioma/*drug therapy/mortality/radiotherapy, Humans, Interferon-beta/administration & dosage, Male, Menogaril/administration & dosage, Middle Aged, Neoplasm Recurrence, Local/*drug therapy/mortality, Procarbazine/administration & dosage, Prognosis, Proportional Hazards Models, Texas/epidemiology, Treatment Outcome, Tretinoin/administration & dosage
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/11550320
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής